Bitget upgrades CFD copy trading feature, now supporting independent take-profit and stop-loss as well as multi-dimensional position modes

On October 6 - Vaccine developer Vaxcyte (PCVX.O) shares fell 1.7% pre-market to $72.60, as the company seeks financing. PCVX launched a public offering on Monday night, including $500 millions in stock and pre-funded warrants, as well as $500 millions in convertible bonds (CBs) due October 15, 2032. On Monday, the PCVX share price soared approximately 31% and closed at $73.82 after the company announced its pneumonia vaccine VAX-31 met all primary endpoints in a late-stage clinical trial, generating immune responses at least comparable to Pfizer’s Prevnar 20 and Merck’s Capvaxive. The company plans to use the net proceeds from both offerings to fund the clinical development of VAX-31’s adult and pediatric programs—including the ongoing phase III adult study for VAX-31—clinical trials for its seasonal flu vaccine (OPUS-2), and other purposes. Jefferies, Leerink, BofA, Evercore, Goldman Sachs, and Guggenheim are joint book-running managers for this equity offering; Jefferies, Leerink, BofA, Goldman Sachs, and Evercore are joint lead underwriters for the convertible bonds. Based in San Carlos, California, PCVX has about 148.8 million shares outstanding and a market capitalization of $11 billions. As of Monday, the stock was up 60% year-to-date. According to London Stock Exchange Group (LSEG) data, out of 10 analysts, 9 rate the stock as “strong buy” or “buy” and 1 as “hold”; the median price target is $122. (For the convenience of non-native English speakers, Reuters provides automated translations of its reports into several other languages. Because automated translation may contain errors or not capture the intended context, Reuters does not guarantee the accuracy of the automated text, which is provided for reader convenience. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)

09:00 AM EDT, 10/06/2026 (MT Newswires) -- Consumer stocks were edging higher premarket Tuesday, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) up 0.1% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) advancing by 0.6%. Nomad Foods (NOMD) stock was up more than 4% after the company said it now expects fiscal 2026 organic revenue to decline 2% to 3%, compared with its previous guidance for a decline of 2% to 5%.

Uber (UBER.US) will acquire food service company ezCater Inc. for $2.3 billion in cash, a move that will help the Uber Eats delivery platform reach more corporate clients.

October 6 – ** Paint manufacturer RPM International (RPM.N) shares fell 2% to close at $93.50 after releasing its first-quarter earnings report ** The company expects mid-single-digit growth in adjusted EBITDA for fiscal year 2027, compared to its previous forecast of 5% to 10% ** The company expects consolidated sales to achieve mid-single-digit growth, roughly in line with the previous estimate of 3% to 7% ** According to LSEG data, net sales for the first quarter were $2.22 billions, meeting analysts’ expectations ** Adjusted earnings per share for the first quarter were $1.98, higher than the expected $1.94 ** Out of 18 brokerages, 17 gave a “buy” or higher rating, 1 gave a “hold” rating; the median price target is $127.94—data compiled by LSEG ** As of the previous trading day’s close, the stock has fallen 8.37% year-to-date (To facilitate non-English speakers, Reuters has automated its reports into several other languages. As automated translations may contain errors or may lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them as a convenience to readers. Reuters assumes no liability for any harm or loss arising from the use of automatic translation functions.)